4DMedical (ASX:4DX) secured Therapeutic Goods Administration (TGA) approval and inclusion on the Australian Register of Therapeutic Goods for its non-contrast ventilation-perfusion imaging software CT:VQ, enabling commercial use across Australia, according to a Friday Australian bourse filing.

The technology derives regional ventilation and perfusion information from standard non-contrast computed tomography (CT) scans without the need for injections, contrast agents, or nuclear medicine infrastructure, per the filing.

The company said CT:VQ is well positioned for scalable adoption across both urban and regional healthcare settings in Australia, where high CT scanner density could help improve access to functional lung imaging, the filing said.

The company will now seek Medicare reimbursement through the Medical Services Advisory Committee, backed by clinical and health-economic evidence as well as real-world usage data, the filing added.